Related Experiment Video
Updated: May 3, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer
I Teneng1, C S Tellez1, M A Picchi1
1Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM, USA.
Abstract:
The maintenance cytosine DNA methyltransferase DNMT1 and de novo methyltransferase DNMT3b cooperate to establish aberrant DNA methylation and chromatin complexes to repress gene transcription during cancer development. The expression of DNMT3b was constitutively increased 5-20-fold in hTERT/CDK4-immortalized human bronchial epithelial cells (HBECs) before treatment with low doses of tobacco carcinogens. Overexpression of DNMT3b increased and accelerated carcinogen-induced transformation. Genome-wide profiling of transformed HBECs identified 143 DNMT3b-target genes, many of which were transcriptionally regulated by the polycomb repressive complex 2 (PRC2) complex and silenced through aberrant methylation in non-small-cell lung cancer cell lines. Two genes studied in detail, MAL and OLIG2, were silenced during transformation, initially through enrichment for H3K27me3 and H3K9me2, commonly methylated in lung cancer, and exert tumor suppressor effects in vivo through modulating cancer-related pathways. Re-expression of MAL and OLIG2 to physiological levels dramatically reduced the growth of lung tumor xenografts. Our results identify a key role for DNMT3b in the earliest stages of initiation and provide a comprehensive catalog of genes targeted for silencing by this methyltransferase in non-small-cell lung cancer.
Insights
DNA methyltransferase DNMT3b drives early cancer development by silencing tumor suppressor genes. Restoring MAL and OLIG2 expression inhibited lung tumor growth, highlighting DNMT3b as a therapeutic target in non-small-cell lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- DNA methylation is crucial for gene regulation and implicated in cancer.
- DNMT1 and DNMT3b are key enzymes in DNA methylation.
- Aberrant DNA methylation contributes to cancer development.
Purpose of the Study:
- To investigate the role of DNMT3b in early stages of lung cancer development.
- To identify DNMT3b-targeted genes silenced during transformation.
- To explore the therapeutic potential of re-expressing silenced tumor suppressor genes.
Main Methods:
- Used hTERT/CDK4-immortalized human bronchial epithelial cells (HBECs) treated with tobacco carcinogens.
- Performed genome-wide profiling to identify DNMT3b target genes.
- Utilized in vivo xenograft models to assess tumor suppressor gene function.
Main Results:
- DNMT3b expression increased significantly in pre-cancerous cells, accelerating carcinogen-induced transformation.
- Identified 143 DNMT3b target genes, many regulated by PRC2 and silenced via methylation in non-small-cell lung cancer (NSCLC).
- Re-expression of tumor suppressors MAL and OLIG2 inhibited lung tumor xenograft growth.
Conclusions:
- DNMT3b plays a critical role in the initiation of lung cancer by establishing aberrant DNA methylation.
- Provides a comprehensive catalog of DNMT3b-silenced genes in NSCLC.
- MAL and OLIG2 function as tumor suppressors, and their re-expression offers a potential therapeutic strategy for NSCLC.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
MicroRNAs
MicroRNAs

